Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

June 22, 2020

Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies

June 22, 2020

Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor

June 18, 2020

Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors

June 9, 2020

Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510

May 19, 2020

Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II

May 14, 2020

Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress

April 29, 2020

Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models

March 18, 2020

Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program

March 9, 2020

New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute

February 18, 2020

Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Next page
Last page

Displaying 11 - 20 of 45

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2020 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063

Search Investor Relations